- Home
- MEIP vs CLDI Comparison
MEIP vs CLDI Comparison
Compare MEIP & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- CLDI
- Stock Information
- Founded
- MEIP 2000
- CLDI 2014
- Country
- MEIP United States
- CLDI United States
- Employees
- MEIP N/A
- CLDI N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MEIP Health Care
- CLDI Health Care
- Exchange
- MEIP Nasdaq
- CLDI Nasdaq
- Market Cap
- MEIP 13.3M
- CLDI 15.7M
- IPO Year
- MEIP 2003
- CLDI N/A
- Fundamental
- Price
- MEIP $2.16
- CLDI $0.41
- Analyst Decision
- MEIP Hold
- CLDI Strong Buy
- Analyst Count
- MEIP 1
- CLDI 2
- Target Price
- MEIP N/A
- CLDI $15.00
- AVG Volume (30 Days)
- MEIP 6.0K
- CLDI 202.0K
- Earning Date
- MEIP 05-13-2025
- CLDI 05-20-2025
- Dividend Yield
- MEIP N/A
- CLDI N/A
- EPS Growth
- MEIP N/A
- CLDI N/A
- EPS
- MEIP N/A
- CLDI N/A
- Revenue
- MEIP N/A
- CLDI N/A
- Revenue This Year
- MEIP N/A
- CLDI N/A
- Revenue Next Year
- MEIP N/A
- CLDI N/A
- P/E Ratio
- MEIP N/A
- CLDI N/A
- Revenue Growth
- MEIP 33.76
- CLDI N/A
- 52 Week Low
- MEIP $1.46
- CLDI $0.35
- 52 Week High
- MEIP $4.10
- CLDI $4.90
- Technical
- Relative Strength Index (RSI)
- MEIP 60.32
- CLDI 36.62
- Support Level
- MEIP $2.01
- CLDI $0.40
- Resistance Level
- MEIP $2.08
- CLDI $0.46
- Average True Range (ATR)
- MEIP 0.10
- CLDI 0.04
- MACD
- MEIP 0.03
- CLDI 0.00
- Stochastic Oscillator
- MEIP 100.00
- CLDI 9.73
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.